Ariel Werman

Title: Ariel Werman: Innovator in Glycan-Modified Receptors and Hepatitis B Research.

Introduction

Ariel Werman is a notable inventor based in Jerusalem, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of glycan-modified soluble receptors and methods for inhibiting the release of hepatitis B virus from liver cells. With a total of 2 patents, Werman's work has the potential to impact medical treatments and therapeutic approaches.

Latest Patents

Werman's latest patents include two innovative inventions. The first is titled "Glycan modified soluble receptors and binding protein and their use." This invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein, or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc, or GalNAc. The second patent is "Method for inhibiting release of hepatitis B virus from liver cells." This invention focuses on the use of the soluble LDL receptor (sLDLR) in addressing viral hepatitis.

Career Highlights

Throughout his career, Ariel Werman has worked with Yeda Research and Development Company, where he has been able to apply his expertise in biotechnology and innovation. His work has contributed to advancements in understanding and treating viral infections.

Collaborations

Werman has collaborated with notable individuals in his field, including Menachem Rubinstein and Ben Alkahe. These partnerships have likely enhanced his research and development efforts.

Conclusion

Ariel Werman is a distinguished inventor whose work in glycan-modified receptors and hepatitis B research showcases his commitment to advancing medical science. His contributions are paving the way for new therapeutic strategies and innovations in biotechnology.